Amputation for Musculoskeletal... DRG 475 Reimbursement

Acute perioperative interventions to reduce major complications and reoperations after lower-extremity amputations: randomized or pragmatic trials testing perioperative bundles (optimizing hemostasis, antibiotic timing/duration, multimodal analgesia, and VTE prophylaxis) in adult patients undergoing transtibial or transfemoral amputation for infection, ischemia, or diabetic foot disease. These studies focus on the immediate inpatient period to lower rates of surgical site infection, flap/graft failure, and unplanned return to OR, which drives length of stay and high variable costs in this DRG; results inform protocols that affect indexing, resource use, and short-term reimbursement risk.
Comparative effectiveness studies of limb-level selection and surgical technique on short-term morbidity and discharge disposition: observational registries or pragmatic comparative trials evaluating outcomes of different levels of amputation (toe/partial foot versus transtibial versus transfemoral), closure methods, and use of revascularization prior to amputation in heterogeneous populations with peripheral arterial disease and diabetes. These studies investigate which approaches achieve better stump healing, lower readmission and prosthetic candidacy rates, and more favorable discharge destinations (home vs skilled nursing), providing evidence for clinicians and payers about interventions that influence inpatient resource intensity and post-acute cost trajectories.
Post-discharge outcomes and rehabilitation pathway research to reduce readmissions and long-term disability: cohort studies and randomized trials of structured inpatient-to-community transitions, early prosthetic fitting programs, infection surveillance, and targeted home health or multidisciplinary diabetic foot clinics for patients who underwent amputation with complicating comorbidities. By measuring 30–90 day readmissions, wound-related complications, functional independence, and downstream utilization, this research area is directly relevant to hospital case-mix management and payers aiming to lower total episode spending and improve value for patients classified under this DRG.

Acute perioperative interventions to reduce major complications and reoperations after lower-extremity amputations: randomized or pragmatic trials testing perioperative bundles (optimizing hemostasis, antibiotic timing/duration, multimodal analgesia, and VTE prophylaxis) in adult patients undergoing transtibial or transfemoral amputation for infection, ischemia, or diabetic foot disease. These studies focus on the immediate inpatient period to lower rates of surgical site infection, flap/graft failure, and unplanned return to OR, which drives length of stay and high variable costs in this DRG; results inform protocols that affect indexing, resource use, and short-term reimbursement risk.
Comparative effectiveness studies of limb-level selection and surgical technique on short-term morbidity and discharge disposition: observational registries or pragmatic comparative trials evaluating outcomes of different levels of amputation (toe/partial foot versus transtibial versus transfemoral), closure methods, and use of revascularization prior to amputation in heterogeneous populations with peripheral arterial disease and diabetes. These studies investigate which approaches achieve better stump healing, lower readmission and prosthetic candidacy rates, and more favorable discharge destinations (home vs skilled nursing), providing evidence for clinicians and payers about interventions that influence inpatient resource intensity and post-acute cost trajectories.
Post-discharge outcomes and rehabilitation pathway research to reduce readmissions and long-term disability: cohort studies and randomized trials of structured inpatient-to-community transitions, early prosthetic fitting programs, infection surveillance, and targeted home health or multidisciplinary diabetic foot clinics for patients who underwent amputation with complicating comorbidities. By measuring 30–90 day readmissions, wound-related complications, functional independence, and downstream utilization, this research area is directly relevant to hospital case-mix management and payers aiming to lower total episode spending and improve value for patients classified under this DRG.

OpenPayer

Summary & Overview

Amputation for Musculoskeletal System and Connective Tissue Disorders with CC: Inpatient Reimbursement Overview

DRG 475 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes